View all cases
ACT 16112/2024
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- Status—ActionInfringementCategoryMain Infringement Action
- Parties
- Claimants
- Sanofi SA (successor of Sanofi Mature IP)
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Reps: Frédéric Chevallier (McDermott Will & Schulte)Respondents- Accord Healthcare B.V.
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare Italia Srl
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Judges
- Matthias Zigann · Presiding Judge and Judge-Rapporteur
- Technology
- Pharmaceuticals · Oncology · Pharmaceutical & Medical
- Language
- —
- First decided
- Sep 15, 2025
Decisions
- 2025-09-15Infringement Action
The Munich Local Division issued a post-interim-conference procedural order in consolidated infringement actions by Sanofi (and successor entities) against multiple generic companies (Accord, STADA, Dr Reddy's, Zentiva) relating to EP 2 493 466 (UPC_CFI_145–503/2024 group). The order confirmed oral hearing dates (14–17 October 2025) and directed that the four counterclaims for revocation be heard together while each infringement action is heard separately.
Legal issues:Scheduling of consolidated oral hearingsJoint hearing of counterclaims with separate infringement actionsPharmaceutical patent — multiple generic defendants
Documents
- E79ADC9623FEEA58E3BCCD3E3CEC9B1C_en.pdf2025-09-15EN